Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
13 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
11 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
11 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degr
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
05 déc. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
26 nov. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
13 nov. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
07 nov. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
28 oct. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
23 oct. 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
28 août 2024 07h00 HE
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences